Drug derived from sea squirt shows anti-tumour activity

An article published early online on 21 June 2007 in the The Lancet Oncology "Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study" concluded that the drug, trabectedin, derived from sea-squirt shows anti-tumour activity in more than half of patients with advanced pre-treated myxoid liposarcomas, a specific type of cancer associated with chromosomal translocations. Read more.